Acarix AB (”Acarix” or the "Company") has, as previously announced, completed the rights issue of
shares amounting to approximately SEK 56 million, which was announced on 15 July 2020 and
approved by the extraordinary general meeting on 11 August 2020 (the ”Rights Issue”). In
connection herewith, in accordance with the guarantee undertakings that have been entered into,
a directed issue of shares is carried out to the guarantors in the Rights Issue who have chosen to
receive guarantee commission in the form of newly issued shares in the Company (the
“Compensation Issue"). The subscription price in the Compensation Issue is set at SEK 0.712 per
share and payment is made through set-off of the guarantors' claims.
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.